Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Catherine Berry

Showing results (31-40 of 37) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 37 results.
Antimicrobial Agents and Chemotherapy|June 6, 2024
How much should we still worry about QTc prolongation in rifampicin-resistant tuberculosis? ECG findings from TB-PRACTECAL clinical trialIlaria Motta, Martina Cusinato, Andrew J Ludman, et al.
The Lancet. Global Health|January 31, 2025
24-week, all-oral regimens for pulmonary rifampicin-resistant tuberculosis in TB-PRACTECAL trial sites: an economic evaluationSedona Sweeney, Yoko V Laurence, Catherine Berry, et al.
The European Respiratory Journal|July 17, 2025
Optimal dosing and duration of linezolid for the treatment of multidrug-resistant and rifampicin-resistant tuberculosis: an individual patient data meta-analysisNakwon Kwak, Joong-Yub Kim, Areum Han, et al.
The New England Journal of Medicine|January 29, 2025
Oral Regimens for Rifampin-Resistant, Fluoroquinolone-Susceptible TuberculosisLorenzo Guglielmetti, Uzma Khan, Gustavo E Velásquez, et al.
The Lancet. Respiratory Medicine|July 19, 2025
Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trialLorenzo Guglielmetti, Uzma Khan, Gustavo E Velásquez, et al.
Biorxiv : the Preprint Server for Biology|March 10, 2021
Vaccination with SARS-CoV-2 Spike Protein and AS03 Adjuvant Induces Rapid Anamnestic Antibodies in the Lung and Protects Against Virus Challenge in Nonhuman PrimatesJoseph R Francica, Barbara J Flynn, Kathryn E Foulds, et al.
Science Translational Medicine|July 28, 2021
Protective antibodies elicited by SARS-CoV-2 spike protein vaccination are boosted in the lung after challenge in nonhuman primatesJoseph R Francica, Barbara J Flynn, Kathryn E Foulds, et al.
Pageof 4

Showing results (31-40 of 37) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 37 results.
Antimicrobial Agents and Chemotherapy|June 6, 2024
How much should we still worry about QTc prolongation in rifampicin-resistant tuberculosis? ECG findings from TB-PRACTECAL clinical trialIlaria Motta, Martina Cusinato, Andrew J Ludman, et al.
The Lancet. Global Health|January 31, 2025
24-week, all-oral regimens for pulmonary rifampicin-resistant tuberculosis in TB-PRACTECAL trial sites: an economic evaluationSedona Sweeney, Yoko V Laurence, Catherine Berry, et al.
The European Respiratory Journal|July 17, 2025
Optimal dosing and duration of linezolid for the treatment of multidrug-resistant and rifampicin-resistant tuberculosis: an individual patient data meta-analysisNakwon Kwak, Joong-Yub Kim, Areum Han, et al.
The New England Journal of Medicine|January 29, 2025
Oral Regimens for Rifampin-Resistant, Fluoroquinolone-Susceptible TuberculosisLorenzo Guglielmetti, Uzma Khan, Gustavo E Velásquez, et al.
The Lancet. Respiratory Medicine|July 19, 2025
Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trialLorenzo Guglielmetti, Uzma Khan, Gustavo E Velásquez, et al.
Biorxiv : the Preprint Server for Biology|March 10, 2021
Vaccination with SARS-CoV-2 Spike Protein and AS03 Adjuvant Induces Rapid Anamnestic Antibodies in the Lung and Protects Against Virus Challenge in Nonhuman PrimatesJoseph R Francica, Barbara J Flynn, Kathryn E Foulds, et al.
Science Translational Medicine|July 28, 2021
Protective antibodies elicited by SARS-CoV-2 spike protein vaccination are boosted in the lung after challenge in nonhuman primatesJoseph R Francica, Barbara J Flynn, Kathryn E Foulds, et al.
Pageof 4